Genfit's (GNFT) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genfit (NASDAQ:GNFT - Free Report) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $11.00 price target on the stock.

Genfit Stock Down 2.6 %

Shares of NASDAQ GNFT traded down $0.10 during mid-day trading on Friday, reaching $3.52. The company had a trading volume of 14,247 shares, compared to its average volume of 17,002. Genfit has a one year low of $2.89 and a one year high of $4.75. The business's 50-day simple moving average is $3.67 and its 200 day simple moving average is $3.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Envestnet Asset Management Inc. grew its position in Genfit by 561.4% in the first quarter. Envestnet Asset Management Inc. now owns 175,634 shares of the company's stock valued at $50,000 after acquiring an additional 149,080 shares during the last quarter. Optiver Holding B.V. grew its position in Genfit by 2,229.2% in the fourth quarter. Optiver Holding B.V. now owns 82,359 shares of the company's stock valued at $315,000 after acquiring an additional 78,823 shares during the last quarter. Citadel Advisors LLC grew its position in Genfit by 181.8% in the third quarter. Citadel Advisors LLC now owns 35,319 shares of the company's stock valued at $129,000 after acquiring an additional 22,786 shares during the last quarter. OLD Mission Capital LLC bought a new position in Genfit in the fourth quarter valued at about $48,000. Finally, BNP Paribas Arbitrage SNC grew its position in Genfit by 1,992.8% in the third quarter. BNP Paribas Arbitrage SNC now owns 11,845 shares of the company's stock valued at $43,000 after acquiring an additional 11,279 shares during the last quarter. Institutional investors own 2.24% of the company's stock.

Genfit Company Profile

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.